Opinion|Videos|January 17, 2025
Integrating Emerging BTKi Therapies Into Current Treatment Guidelines
Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the clinical implications of these trials, and which unmet needs are being addressed or potentially fulfilled in the MCL landscape?
- In the context of the evolving treatment landscape, how do you envision the integration of emerging BTKi therapies impacting current treatment guidelines for CLL and MCL? What factors should be considered?
Advertisement
Related to this article
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
3
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
4
PBM Satisfaction Stalls as Net Promoter Score Turns Negative
5